DE69730796T2 - Naphthylverbindungen, Zusammensetzungen und Verfahren - Google Patents
Naphthylverbindungen, Zusammensetzungen und Verfahren Download PDFInfo
- Publication number
- DE69730796T2 DE69730796T2 DE69730796T DE69730796T DE69730796T2 DE 69730796 T2 DE69730796 T2 DE 69730796T2 DE 69730796 T DE69730796 T DE 69730796T DE 69730796 T DE69730796 T DE 69730796T DE 69730796 T2 DE69730796 T2 DE 69730796T2
- Authority
- DE
- Germany
- Prior art keywords
- compound
- formula
- alkyl
- symptoms
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 125000001624 naphthyl group Chemical group 0.000 title abstract 2
- 230000001575 pathological effect Effects 0.000 claims abstract 4
- 239000000262 estrogen Substances 0.000 claims abstract 3
- 229940011871 estrogen Drugs 0.000 claims abstract 3
- 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract 2
- 206010028980 Neoplasm Diseases 0.000 claims abstract 2
- 208000001132 Osteoporosis Diseases 0.000 claims abstract 2
- 201000011510 cancer Diseases 0.000 claims abstract 2
- 230000001419 dependent effect Effects 0.000 claims abstract 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims 15
- 239000003814 drug Substances 0.000 claims 11
- 208000024891 symptom Diseases 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 206010027304 Menopausal symptoms Diseases 0.000 claims 4
- -1 methyl-1-pyrrolidinyl Chemical group 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 241001024304 Mino Species 0.000 claims 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 208000016599 Uterine disease Diseases 0.000 claims 1
- 210000000709 aorta Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 201000010260 leiomyoma Diseases 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 239000000583 progesterone congener Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 208000006386 Bone Resorption Diseases 0.000 abstract 1
- 206010065687 Bone loss Diseases 0.000 abstract 1
- 230000024279 bone resorption Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 0 Cc(cc1)cc(cc2)c1c(-c1cccc(**)c1)c2-c1ccc(*)cc1 Chemical compound Cc(cc1)cc(cc2)c1c(-c1cccc(**)c1)c2-c1ccc(*)cc1 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2948496P | 1996-10-24 | 1996-10-24 | |
| US29484P | 1996-10-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69730796D1 DE69730796D1 (de) | 2004-10-28 |
| DE69730796T2 true DE69730796T2 (de) | 2005-09-29 |
Family
ID=21849243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69730796T Expired - Fee Related DE69730796T2 (de) | 1996-10-24 | 1997-10-22 | Naphthylverbindungen, Zusammensetzungen und Verfahren |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US5952350A (enExample) |
| EP (1) | EP0838459B1 (enExample) |
| JP (1) | JPH10130212A (enExample) |
| AT (1) | ATE277026T1 (enExample) |
| CA (1) | CA2215647A1 (enExample) |
| DE (1) | DE69730796T2 (enExample) |
| ES (1) | ES2227654T3 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL120266A (en) | 1996-02-28 | 2005-05-17 | Pfizer | Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions |
| EP1142862A3 (en) * | 1996-08-29 | 2002-10-02 | Eli Lilly And Company | Naphthyl and tetralone derivatives as intermediates |
| ID19392A (id) | 1996-08-29 | 1998-07-09 | Lilly Co Eli | Senyawa naftil dan bahan pertengahan serta komposisi dan metode penggunaan |
| EP1004306A3 (en) * | 1998-08-06 | 2000-06-07 | Pfizer Products Inc. | Estrogen agonists/antagonists |
| US7001926B2 (en) * | 2000-03-10 | 2006-02-21 | Oxigene, Inc. | Tubulin binding agents and corresponding prodrug constructs |
| US7091240B2 (en) * | 2000-03-10 | 2006-08-15 | Oxigene, Inc. | Tubulin binding ligands and corresponding prodrug constructs |
| US6610705B1 (en) * | 2000-03-31 | 2003-08-26 | Council Of Scientific And Industrial Research | Process for the preparation of diaryl naphthyl methanes |
| US20050245489A1 (en) * | 2004-05-03 | 2005-11-03 | Pinney Kevin G | Chromene-containing compounds with anti-tubulin and vascular targeting activity |
| US7456214B2 (en) * | 2004-05-03 | 2008-11-25 | Baylor University | Chromene-containing compounds with anti-tubulin and vascular targeting activity |
| FR2899895B1 (fr) * | 2006-04-12 | 2010-09-17 | Servier Lab | Nouveaux sels de strontium d'acides sulfoniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| CN114133336B (zh) * | 2020-09-03 | 2024-04-02 | 沈阳药科大学 | 4-甲氧基萘取代的苯胺类化合物及其制备方法和应用 |
| CN113620788A (zh) * | 2021-08-11 | 2021-11-09 | 苏州求索生物科技有限公司 | 一种3-甲氧基苯乙基溴的制备方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3274213A (en) * | 1961-09-05 | 1966-09-20 | Upjohn Co | Alkoxy-substituted 2-phenyl-1-(tertiary-aminoalkoxy)phenyl-3, 4-dihydronaphthalenes |
| DE1300575B (de) * | 1965-05-21 | 1969-08-07 | Bristol Myers Co | Benzo[b]thiophene |
| US3394125A (en) * | 1965-10-23 | 1968-07-23 | Bristol Myers Co | 2-phenyl-3-tertiary-aminoalkoxy phenyl-and corresponding tertiaryaminoalkyl thio benzfurans substituted in the benzo nucleus with an alkoxy or tertiaryamino alkoxy or alkylthio group |
| US4133814A (en) * | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
| US4230862A (en) * | 1975-10-28 | 1980-10-28 | Eli Lilly And Company | Antifertility compounds |
| US4358593A (en) * | 1981-04-03 | 1982-11-09 | Eli Lilly And Company | Process for preparing 3-(4-aminoethoxybenzoyl)benzo[b]thiophenes |
| PH18628A (en) * | 1981-04-03 | 1985-08-23 | Lilly Co Eli | "6-hydroxy-2-(4-hydroxyphenyl)-3 4-(2- piperidine or 3-methylpyrollidine -benzo b thiophene compounds |
| US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
| US4380635A (en) * | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
| US4916126A (en) * | 1987-09-25 | 1990-04-10 | Ciba-Geigy Corporation | Diacyl derivatives of 4-(trialkylbenzyl)-piperazinyl compounds |
| US5395842A (en) * | 1988-10-31 | 1995-03-07 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
| DE4117512A1 (de) * | 1991-05-25 | 1992-11-26 | Schering Ag | 2-phenylbenzo(b)furane und -thiophene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate |
| US5147880A (en) * | 1991-07-22 | 1992-09-15 | Eli Lilly And Company | Benzo[a]fluorene compounds |
| JP3157882B2 (ja) * | 1991-11-15 | 2001-04-16 | 帝国臓器製薬株式会社 | 新規なベンゾチオフエン誘導体 |
| US6756388B1 (en) * | 1993-10-12 | 2004-06-29 | Pfizer Inc. | Benzothiophenes and related compounds as estrogen agonists |
| US7501441B1 (en) * | 1994-09-20 | 2009-03-10 | Eli Lilly And Company | Naphthyl compounds, intermediates, processes, compositions, and methods |
| US5552412A (en) * | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
| US6451817B1 (en) * | 1995-03-10 | 2002-09-17 | Eli Lilly And Company | Alpha-substituted-1-benzyl-napthyls |
-
1997
- 1997-09-11 CA CA002215647A patent/CA2215647A1/en not_active Abandoned
- 1997-10-22 AT AT97308375T patent/ATE277026T1/de not_active IP Right Cessation
- 1997-10-22 ES ES97308375T patent/ES2227654T3/es not_active Expired - Lifetime
- 1997-10-22 JP JP9289614A patent/JPH10130212A/ja active Pending
- 1997-10-22 DE DE69730796T patent/DE69730796T2/de not_active Expired - Fee Related
- 1997-10-22 EP EP97308375A patent/EP0838459B1/en not_active Expired - Lifetime
- 1997-10-23 US US08/956,678 patent/US5952350A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ATE277026T1 (de) | 2004-10-15 |
| CA2215647A1 (en) | 1998-04-24 |
| JPH10130212A (ja) | 1998-05-19 |
| EP0838459A1 (en) | 1998-04-29 |
| DE69730796D1 (de) | 2004-10-28 |
| ES2227654T3 (es) | 2005-04-01 |
| US5952350A (en) | 1999-09-14 |
| EP0838459B1 (en) | 2004-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69526550T2 (de) | 2-(4-Hydroxyphenyl)-benzothiophen-Derivate, Zubereitungen und Methoden zur Milderung der Symptome des post-menopausalen Syndroms | |
| DE69525699T2 (de) | Naphthyl-Derivate, Zwischenprodukte, Verfahren, Zusammensetzungen, die sie enthalten | |
| DE69310288T2 (de) | Verbesserungen bezüglich Benzothiophenen | |
| DE69606566T2 (de) | Pharmazeutische Benzofuranverbindungen | |
| DE69418639T2 (de) | Sulfonat- und Carbamatderivate von 3-aroyl-benzo(beta)Thiophenen | |
| DE69616396T2 (de) | Benzothiophen-Verbindungen, Zwischenprodukte, Zusammensetzungen und Verfahren | |
| DE69611015T2 (de) | Pentazyklische Verbindungen, Zwischenprodukte, Verfahren, Zubereitungen und Methode | |
| DE69629624T2 (de) | Verbindungen mit stickstoffenthaltenden nichtbasischen Seitenketten und diese enthaltende Zubereitungen | |
| DE69628246T2 (de) | Naphthyl- und Dihydronaphthylverbindungen als Arzneimittel | |
| DE69730796T2 (de) | Naphthylverbindungen, Zusammensetzungen und Verfahren | |
| DE69532079T2 (de) | Benzofuranverbindungen, präparate und verfahren | |
| DE69724733T2 (de) | Substituierte Benzo(b)thiophene als selektive Östrogenrezeptormodulatoren | |
| DE69611452T2 (de) | Benzothiophenderivate | |
| DE69825381T2 (de) | Benzothiophene | |
| DE69731043T2 (de) | Benzo[B]thiophen-Verbindungen, Zwischenprodukte, Verfahren und Zusammensetzungen | |
| DE69706386T2 (de) | 2-Aryl-3-Aminoaryloxynaphthylverbindungen, Zwischenverbindungen, Zusammensetzungen und Verfahren | |
| DE69724062T2 (de) | Benzothiophenderivate, Zwischenprodukte, Verfahren, Zubereitungen und Methoden | |
| DE69600709T2 (de) | Verbindungen mit N-Acyliertem Piperidin in der Seitenkette und Zusammensetzungen | |
| DE69726513T2 (de) | Benzo[B]thiophenverbindungen,Zwischenprodukte,Verfahren,Zusammensetzungen und Methode | |
| DE69629500T2 (de) | Benzothiophene Verbindungen als Pharmazeutika | |
| DE69724548T2 (de) | Substituierte 2,3-Aryl-Benzothiophene und ihre östrogene Aktivität | |
| DE60005693T2 (de) | Eine kristalline form von 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophen-hydrochlorid | |
| DE69708418T2 (de) | Naphthylverbindungen und Zusammensetzungen | |
| DE60210283T2 (de) | 2-substituierte 1,2,3,4-tetrahydrochinoline und derivate davon, zusammensetzungen und verfahren | |
| DE69723639T2 (de) | Benzothiophenverbindungen, Zubereitungen und Verfahren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |